세계의 무세포 단백질 발현(CFPE) 시장 : 제품별, 방법별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global cell-free protein expression market size reached USD 283.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 515.1 Million by 2033, exhibiting a growth rate (CAGR) of 6.52% during 2025-2033. The market is experiencing significant growth mainly driven by advancements in personalized medicine, vaccine development, and synthetic biology. The rising demand for cost-effective, flexible solutions in pharmaceuticals and biotechnology further propels market growth, positioning CFPE as a key industry enabler.

Cell-free protein expression (CFPE) refers to the production of desired recombinant proteins in solution using biomolecular translation machinery extracted from cells. It can be carried out using different cell lysates, such as E. coli, rabbit reticulocytes, wheat germ, insect cells, and mammalian cell-free protein expression systems. They are widely used in enzyme engineering, protein labeling, protein purification, protein-protein interaction, and high throughput production of mutants. CFPE is also used for analyzing components needed for protein stability, degradation, and folding. As compared to cell-based protein expression, cell-free protein expression is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity.

Cell-free Protein Expression Market Trends:

The rapid advancement in biological sciences is one of the key factors driving the market growth. Cell-free protein expression is extensively used in the expansion of genetic code, assembly of viruses, and the synthesis of recombinant proteins for various biomolecular processes. Furthermore, the increasing technique utilization in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer and infectious diseases is acting as another growth-inducing factor. Additionally, the integration of machine learning (ML) algorithms to improve protein production yield by optimizing the system for efficient prototyping and high-throughput experimentation is providing an impetus to market growth. Moreover, the introduction of novel processes to produce complex prokaryotic and eukaryotic proteins using a continuous-exchange cell-free (CECF) protein synthesis system is creating a positive outlook for the market. Other factors, including the widespread adoption of cell-free methods for biomanufacturing and prototyping, extensive research and development (R&D) activities in proteomics and genomics, and the rising adoption in the healthcare industry for diagnostic applications, such as pathogen sensing, inflammatory response, and personalized medicine, are supporting drive the market growth.

Key Market Segmentation:

Breakup by Product:

• Expression Systems
• E. coli Cell-free Protein Expression System
• Wheat Germ Cell-free Protein Expression System
• Rabbit Reticulocytes Cell-free Protein Expression System
• Insect Cells Cell-free Protein Expression System
• Human Cell-free Protein Expression System
• Others
• Reagents

Breakup by Method:

• Transcription and Translation Systems
• Translation Systems

Breakup by Application:

• Enzyme Engineering
• High Throughput Production
• Protein Labeling
• Protein-Protein Interaction
• Protein Purification

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bioneer Corporation, biotechrabbit GmbH, Cambridge Isotope Laboratories Inc. (Otsuka Pharmaceutical Co. Ltd.), CellFree Sciences Co. Ltd., Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Merck KGaA, New England Biolabs, Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global cell-free protein expression market in 2024?
• 2.What is the expected growth rate of the global cell-free protein expression market during 2025-2033?
• 3.What are the key factors driving the global cell-free protein expression market?
• 4.What has been the impact of COVID-19 on the global cell-free protein expression market?
• 5.What is the breakup of the global cell-free protein expression market based on the product?
• 6.What is the breakup of the global cell-free protein expression market based on the method?
• 7.What is the breakup of the global cell-free protein expression market based on application?
• 8.What is the breakup of the global cell-free protein expression market based on the end user?
• 9.What are the key regions in the global cell-free protein expression market?
• 10.Who are the key players/companies in the global cell-free protein expression market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cell-free Protein Expression Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Expression Systems
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 E. coli Cell-free Protein Expression System
    • 6.1.2.2 Wheat Germ Cell-free Protein Expression System
    • 6.1.2.3 Rabbit Reticulocytes Cell-free Protein Expression System
    • 6.1.2.4 Insect Cells Cell-free Protein Expression System
    • 6.1.2.5 Human Cell-free Protein Expression System
    • 6.1.2.6 Others
  • 6.1.3 Market Forecast
• 6.2 Reagents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Method

• 7.1 Transcription and Translation Systems
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Translation Systems
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Enzyme Engineering
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 High Throughput Production
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Protein Labeling
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Protein-Protein Interaction
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Protein Purification
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academic and Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bioneer Corporation
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
  • 15.3.2 biotechrabbit GmbH
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Cambridge Isotope Laboratories Inc. (Otsuka Pharmaceutical Co. Ltd.)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 CellFree Sciences Co. Ltd.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Cube Biotech GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 GeneCopoeia Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Jena Bioscience GmbH
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Merck KGaA
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 New England Biolabs
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Promega Corporation
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Takara Bio Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis